What is Oncodesign Precision Medicine Days Payable?
Oncodesign Precision MedicineFRA:ZR8 32 Days Payable is 203.45 as of Dec. 2025, which is 147% above its 10-year median of 82.50. GuruFocus rates FRA:ZR8 with a GF Score™ of 32/100 and a GF Value™ of €0.26 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 701 Biotechnology companies, Oncodesign Precision Medicine ranks worse than 142653.21% on this metric.
The historical rank and industry rank for Oncodesign Precision Medicine's Days Payable or its related term are showing as below:
During the past 6 years, Oncodesign Precision Medicine's highest Days Payable was 143.87. The lowest was 46.03. And the median was 82.50.
FRA:ZR8's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.84 * Ranked among companies with meaningful Days Payable only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ZR8 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Oncodesign Precision Medicine's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncodesign Precision Medicine Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's Days Payable distribution charts can be found below:
* The bar in red indicates where Oncodesign Precision Medicine's Days Payable falls into.
Oncodesign Precision Medicine Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncodesign Precision Medicine (FRA:ZR8) has a Days Payable of 203.45 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Oncodesign Precision Medicine and its competitors. This is 147% above median its historical median of 82.50. Over the past decade, Oncodesign Precision Medicine's Days Payable has ranged from 46.03 to 143.87. According to the industry distribution chart, Oncodesign Precision Medicine ranks #999999 out of 701 companies in the Biotechnology industry.
Is Oncodesign Precision Medicine's Days Payable too high?
Oncodesign Precision Medicine's current Days Payable of 203.45 is 147% above median its 10-year median of 82.50. Over the past 10 years, this metric has ranged from a low of 46.03 to a high of 143.87. The Biotechnology industry median Days Payable is 112.84. Oncodesign Precision Medicine's value of 203.45 is 80.3% above this industry median. Based on the distribution chart, Oncodesign Precision Medicine ranks #999999 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncodesign Precision Medicine has a GF Score™ of 32/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncodesign Precision Medicine's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncodesign Precision Medicine ranks #999999 out of 701 companies for Days Payable. This places Oncodesign Precision Medicine in the lower half of its industry. The industry median Days Payable is 112.84. Oncodesign Precision Medicine's value of 203.45 is 80.3% above this benchmark. Historically, Oncodesign Precision Medicine's own Days Payable has ranged from 46.03 to 143.87 over the past decade. While the company's 10-year median is 82.50 vs. the industry median of 112.84, Oncodesign Precision Medicine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncodesign Precision Medicine's current Days Payable of 203.45 is 80.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Oncodesign Precision Medicine and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncodesign Precision Medicine's current Days Payable is 203.45, which is 147% above median its own 10-year median of 82.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncodesign Precision Medicine stock overvalued right now?
Based on GuruFocus' analysis, Oncodesign Precision Medicine (FRA:ZR8) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.26, compared to a current price of €0.30 — trading 16.9% above its estimated fair value. The current Days Payable is 203.45, which is 147% above median its 10-year median of 82.50 and 80.3% above the Biotechnology industry median of 112.84. Oncodesign Precision Medicine's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Oncodesign Precision Medicine (FRA:ZR8), the current Days Payable is 203.45 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncodesign Precision Medicine (FRA:ZR8) Overvalued in 2026?
Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued.
The current stock price of €0.30 is trading 16.9% above its estimated GF Value™ of €0.26.
GuruFocus considers Oncodesign Precision Medicine to be Modestly Overvalued.
Key valuation signals for FRA:ZR8:
Days Payable: 203.45 (147% above median its 10-year median of 82.50)
GF Value™: €0.26 vs. price of €0.30 (16.9% above fair value)
Industry Position: 80.3% above the Biotechnology median (#999999 of 701)
No single metric tells the full story. See the FRA:ZR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncodesign Precision Medicine Business Description
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
32GF Score
Get the complete analysis for FRA:ZR8
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZR8 has been successfully added to your 
